Patents Assigned to Genentech, Inc.
  • THERAPY OF PLATINUM-RESISTANT CANCER
    Publication number: 20120107391
    Abstract: The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.
    Type: Application
    Filed: December 1, 2011
    Publication date: May 3, 2012
    Applicant: Genentech, Inc.
    Inventor: STEPHEN M. KELSEY
  • Mediators of hedgehog signaling pathways, compositions and uses related thereto
    Patent number: 8168653
    Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: May 1, 2012
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. Mackinnon
  • Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
    Patent number: 8168633
    Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: May 1, 2012
    Assignee: Genentech, Inc.
    Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
  • Arylsulfonamide compounds
    Patent number: 8168645
    Abstract: The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mimic the biological activity of BH3-only proteins and are capable of binding to and neutralizing pro-survival Bcl-2 proteins: wherein A1, A2, B1, B2, B3, X, Z, R1, R2, R3 and t are as described herein. The invention also relates to processes of preparing the benzenesulfonamide compounds that mimic portions of peptides and proteins, and to the use of such compounds in the regulation of cell death and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: May 1, 2012
    Assignee: Genentech, Inc.
    Inventors: Jonathan Bayldon Baell, Guillaume Laurent Lessene, Brad Edmund Sleebs, Wayne J. Fairbrother, John A. Flygare, Michael F. T. Koehler
  • METHODS AND COMPOSITIONS FOR MODULATING THE WNT PATHWAY
    Publication number: 20120100562
    Abstract: The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.
    Type: Application
    Filed: October 19, 2011
    Publication date: April 26, 2012
    Applicant: Genentech, Inc.
    Inventors: Eric Bourhis, Andrea Cochran, Yingnan Zhang
  • Polypeptide variants with altered effector function
    Patent number: 8163882
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventor: Leonard Presta
  • Pyrimidine compounds, compositions and methods of use
    Patent number: 8163763
    Abstract: Disclosed are compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F. T. Koehler, Kevin Hon Luen Lau, Cuong Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao
  • Combination therapy of her expressing tumors
    Patent number: 8163287
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Stephen M. Kelsey
  • Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
    Patent number: 8158625
    Abstract: Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: April 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Georgette Castanedo, David Goldstein, Rama Kondru, Matthew Lucas, Wylie Palmer, Stephen Price, Brian Safina, Pascal Pierre Alexandre Savy, Eileen Mary Seward, Daniel P. Sutherlin, Zachary K. Sweeney
  • Anti-factor B antibodies and their uses
    Patent number: 8158762
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: April 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Menno Van Lookeren Campagne, Laura Deforge
  • Thiazolopyrimidine PI3K inhibitor compounds and methods of use
    Patent number: 8158626
    Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: April 17, 2012
    Assignees: F. Hoffmann-La Roche AG, Genentech, Inc.
    Inventors: Georgette M. Castanedo, Janet L. Gunzner, Kimberly Malesky, Simon Mathieu, Alan G. Olivero, Daniel P. Sutherlin, Shumei Wang, Bing-Yan Zhu, Irina Chuckowree, Adrian Folkes, Sally Oxenford, Nan Chi Wan
  • BIOMARKERS AND METHODS OF TREATMENT
    Publication number: 20120089541
    Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: August 31, 2011
    Publication date: April 12, 2012
    Applicant: Genentech, Inc.
    Inventors: Premal H. Patel, Amy C. Peterson, Robert L. Yauch, Jiping Zha
  • ANTI-CMET ANTAGONISTS
    Publication number: 20120082662
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: July 28, 2011
    Publication date: April 5, 2012
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • ANTI-CMET ANTAGONISTS
    Publication number: 20120082663
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: July 28, 2011
    Publication date: April 5, 2012
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • Antibody fragment-polymer conjugates and uses of same
    Patent number: 8147830
    Abstract: Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Zahra Shahrokh, Gerardo Zapata
  • Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
    Patent number: 8148106
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
  • Tumor treatment
    Patent number: 8147827
    Abstract: The invention concerns an improved method for treating tumor, including cancer, which combines the administration of a chemotherapeutic agent and an antagonist of a gene product the expression of which is upregulated by the chemotherapeutic agent. The invention further concerns methods and means for the diagnosis and classification of tumors, and for the prognosis of the outcome of tumor treatment, and patient response to a particular treatment modality.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventor: Paul Polakis
  • ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using ligand
    Patent number: 8147844
    Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: December 28, 1994
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. de Sauvage
  • REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
    Publication number: 20120076783
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Application
    Filed: November 29, 2011
    Publication date: March 29, 2012
    Applicants: Novartis AG, Genentech, Inc.
    Inventors: Jun LIU, Steven J. Shire
  • METHOD FOR INHIBITING NEURODEGENERATION
    Publication number: 20120076785
    Abstract: Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue.
    Type: Application
    Filed: February 17, 2010
    Publication date: March 29, 2012
    Applicant: GENENTECH, INC.
    Inventors: Anatoly J. Nikolaev, Julie Pinkston-Gosse, Marc Tessier-Lavigne